Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

Neuronetics, Inc.

STIMNASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Nov 18, 2026Accepted Nov 18, 2026, 4:05 PM ESTFiling CIK 1227636Accession 0001193125-26-467079
Share

Structured filing — 4

ownership.xml

Open full document ↗

Filing details

Report period
2026-11-16
Issuer
Neuronetics, Inc.
Issuer CIK
0001227636
Trading symbol
STIM

Reporting owner 1

Name
MUIR GLENN P
Reporting owner CIK
0001181190
Relationship
Director
Address
C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN, PA, 19355

Non-derivative transactions

Non-derivative transactions · 1 reported row
SecurityTransaction dateCodeAmountA / DPrice (USD)Owned afterOwnership
Common Stock2026-11-16A · Form 4175,000A1.31[F1]576,816D
Table key
A · Form 4
Acquisition by grant, award or otherwise under Rule 16b-3(d)
A
Acquired
D
Direct

Footnotes

F1
The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $1.25 to $1.385. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.↩ 1

Signature 1

Signed
/s/ Francis Brown, as Attorney-in-Fact
Date
2026-11-18

Company context

Neuronetics, Inc. is a leader in interventional mental health, combining innovative treatment technologies with direct patient care. Through its NeuroStar® Advanced Therapy system, the company is a leading provider of transcranial magnetic stimulation (“TMS”) treatment and, through Greenbrook, operates one of the largest interventional psychiatry clinic networks in the United States, offering both TMS and SPRAVATO® therapies. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. NeuroStar Advanced Therapy is the leading TMS treatment for major depressive disorder (“MDD”) in adults and is backed by what we believe is the largest clinical data set of any TMS treatment system for depression. Greenbrook treatment centers also offer SPRAVATO® (esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with MDD with acute suicidal ideation or behavior in conjunction with an oral antidepressant. 1

Current securities

Recent company filings

  1. 4/A filingNov 19, 2026
  2. 4 filingNov 16, 2026
  3. 4 filingNov 16, 2026
  4. Entry into a Material Definitive Agreement · Other EventsNov 12, 2026
  5. Entry into a Material Definitive Agreement · Other EventsNov 12, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.